Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management  by Akaza, Hideyuki et al.
50
Copyright © 2014 Asian Pacific Prostate Society (APPS)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://p-international.org/
pISSN: 2287-8882 • eISSN: 2287-903X 
P R O S T A T E  
INTERNATIONAL
Seventh Joint Meeting of K-J-CaP and CaPSURE:  
extending the global initiative to improve prostate  
cancer management 
Hideyuki Akaza, Choung Soo Kim1, Peter Carroll2, In Young Choi3, Byung Ha Chung4, Matthew R. Cooperberg2,  
Yoshihiko Hirao5, Shiro Hinotsu6, Shigeo Horie7, Ji Youl Lee8, Mikio Namiki9, Chi-Fai Ng10, Mizuki Onozawa11,  
Seiichiro Ozono12, Satoru Ueno9, Rainy Umbas13, Dingwei Ye14, Gang Zhu15
Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, The University of Tokyo, 
Tokyo, Japan;  1Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;  2Department of Urology, Helen Diller 
Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA; 3Graduate School of Healthcare Management  & Policy, The  
Catholic University of Korea, Seoul, Korea;  4Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; 5Osaka 
Gyoumeikan Hospital, Osaka, Japan;  6Center for Innovative Clinical Medicine Okayama University Hospital, Japan;  7Department of Urology, Juntendo 
University, Tokyo, Japan ;  8Department of Urology, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea;  9Department 
of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan;  10Division of Urology, Department of 
Surgery, The  Chinese University of Hong Kong, Hong Kong, China;  11Department of Urology, Tokyo-kita Social Insurance Hospital, Tokyo, Japan;  
12Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan;  13Department of Urology, Cipto Mangunkusumo Hospital, University 
of Indonesia, Jakarta, Indonesia;  14Department of Urology, Fudan University Cancer Hospital, Shanghai, China;  15Beijing Hospital of Ministry of Health, 
Beijing, China
This report summarizes the presentations and discussions that took place at the Seventh Joint Meeting of the Korea–Japan Study 
Group of Prostate Cancer (K-J-CaP) and the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) held in Seoul, 
Korea, in September 2013. The original J-CaP and CaPSURE Joint Initiative has now been established since 2007 and since the initial 
collaboration between research teams in the United States (US) and Japan, the project has expanded to include several other Asian 
countries. The objective of the initiative is to analyze and compare data for prostate cancer patients in the participating countries, 
looking at similarities and differences in patient management and outcomes. Until now the focus has been primarily on data 
generated within J-CaP and CaPSURE, both large-scale, longitudinal, observational databases of prostate cancer patients in Japan 
and the US, respectively. This year’s meeting was hosted for the first time in Korea which has recently established its own national 
database–K-CaP–to add to the wealth of data generated by J-CaP and CaPSURE. As a newly-developed database, K-CaP has also 
provided a valuable ‘template’ for other countries, such as China and Indonesia, planning to establish their own national databases 
and this will ultimately allow greater opportunities for international data comparisons. A range of topics was discussed at this Seventh 
Joint Meeting including comparison of outcomes following androgen deprivation therapy or radical prostatectomy in patients with 
localized prostate cancer, the use of active surveillance as a treatment option and the triggers for intervention when employing this 
regimen, patient quality of life during treatment, the impact of comorbidities on outcomes, and a comparison of recent outcomes 
data between J-CaP and CaPSURE. The participants recognized that prostate cancer was now a global disease and therefore major 
insights into understanding and improving the management of this condition would arise from global interactions such as this joint 
initiative. 
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lished and collecting data for many years however when 
creating a new national database ‘from scratch’ there are sev-
eral challenges that need to be overcome to ensure that the 
database is usable by healthcare professionals in the field and 
that the data collected are of value. Dr. Choi, a specialist in 
medical informatics at The Catholic University of Korea, gave 
an overview of the Smart Prostate Cancer Database (SPC-
DB) system that has been developed for K-CaP to collect and 
manage data from five major hospitals in Korea. The five con-
tributing hospitals use a variety of methods for collecting and 
entering the patient data into the K-CaP system depending on 
their available resources. These include Excel spreadsheets 
(Samsung Medical Center and Seoul National University 
Bundang Hospital), a web-based electronic data entry system 
(Severance Hospital and Asan Medical Center) and a Clinical 
Data Warehouse system (Seoul St. Mary Hospital) which al-
lows direct electronic transmission of specific information on 
a patient’s prostate cancer from their medical records. These 
different methods are all supported within the K-CaP data-
base but each presents their own challenges in terms of data 
management. For example, in the case of the Excel system, it 
can be difficult to trace and correct text and data entry errors. 
It was noted that an app has also been developed for the K-
CaP database to make data entry easier.
 Dr. Choi reported that during the database development 
process they had endeavored to create a common data model 
so that each hospital could use the same database structure 
and collect identical information – this would allow for easier 
data comparison in the future. In addition, certain rules had 
been established to ensure uniformity of data collection 
across the participating institutions, notably: the diagnosis 
of prostate cancer is defined as International Statistical Clas-
sification of Diseases (10th revision), code C61; the initial 
prostate-specific antigen (PSA) value is the first PSA mea-
surement obtained after C61 diagnosis; the preoperative PSA 
value is the preoperative biopsy PSA measurement; and the 
patient’s height and weight should be taken from the nurse’s 
report for in-patients. Some data, such as magnetic resonance 
imaging (MRI) or pathology information, undergo verifica-
tion with the electronic medical records (EMR) data. In ad-
dition, programming is also undertaken in some cases to 
convert unstructured EMR reports into a format suitable for 
the database. Each patient is given a unique identifier so this 
can be followed throughout their disease course, for example 
if they change treatment or move from one treatment centre 
to another, and the database updated accordingly. Currently, 
the SPC-DB holds data from 7,198 patients from the five con-
tributing hospitals.
INTRODUCTION
The Japan Study Group of Prostate Cancer (J-CaP) and the Cancer 
of the Prostate Strategic Urologic Research Endeavor (CaPSURE) 
Joint Initiative was established in 2007 and has now held seven 
annual meetings to review ‘real world’ data drawn from these two 
well-established, longitudinal databases. Initially, the objective 
was to analyze and compare data for prostate cancer patients from 
Japan (J-CaP) and the United States (US, CaPSURE) to try and 
identify trends within these different cohorts in terms of patient 
characteristics, treatment approaches and outcomes, and then to 
compare them at a national and global level. However, the initia-
tive has since been expanded to include representatives of other 
Asian countries. Korea has now developed its own national data-
base and both China and Indonesia plan to do the same, which 
will ultimately generate a large pool of patient data for analysis. 
 The J-CaP database was established in 2001 and gathers in-
formation about hormone therapy administered to Japanese 
prostate cancer patients and the outcomes of such treatment. 
The CaPSURE database was founded in 1995 and currently 
contains data on more than 14,000 prostate cancer patients 
treated with various forms of therapy within the US. The Ko-
rea Study Group of Prostate Cancer (K-CaP) currently holds 
data for 7,198 patients who have undergone radical prosta-
tectomy (RP), radiotherapy or hormone therapy. 
 This report summarizes the presentations and discussions 
that took place at the Seventh Joint Meeting of J-CaP and 
CaPSURE held in Seoul, Korea, in September 2013. 
 The meeting was cochaired by Professor Hideyuki Akaza (The 
University of Tokyo, Japan), Professor Peter Carroll (University of 
California, San Francisco, CA, USA) and Professor Choung Soo 
Kim (Asan Medical Center, University of Ulsan College of Medicine, 
Seoul, Korea). The Chairmen noted that the valuable collaboration 
between research teams in the US and Asian countries was con-
tinuing to expand year-on-year with discussions becoming ever 
more productive, providing guidance for healthcare professionals 
and their patients when selecting treatment options for prostate 
cancer at different disease stages. While there were still many im-
portant issues to resolve, this forum allowed meeting participants 
to share the benefit of their experience of prostate cancer manage-
ment in their countries and to discuss the challenges they face.
MEETING REPORTS
1.  Development of the Korean smart prostate cancer 
database system 
Presented by In Young Choi
Both the J-CaP and CaPSURE databases have been estab-
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Dr. Choi advised that to allow the best possible collaboration 
between databases, ideally they should all collect the same 
information and that this should be borne in mind for any 
new national databases. In the case of J-CaP, it was noted that 
at the time the database had been developed (from 2001–
2003), computer facilities were limited and this dictated to a 
certain extent what was possible; now the database is being 
re-structured and new features added.
 In terms of staffing and support to maintain the K-CaP da-
tabase, in addition to Dr. Choi there are six staff working on 
the project: two to extract the data, three working on database 
development and one nurse checking for data anomalies. All 
participants were impressed with how much progress had 
been made with the K-CaP database since it had first been dis-
cussed at the Sixth J-CaP and CaPSURE Joint Meeting in 2012.  
 Dr. Choi noted that while there are similarities between 
the database structures currently in place for K-CaP, J-CaP, 
and CaPSURE in that all of them collect demographic data 
(age, gender, race), body measurements (height, weight, body 
mass index) and clinical history (any comorbidities, medica-
tions, surgical history, family history), there are also notable 
differences (Table 1). Only CaPSURE collects data on the use 
of complementary and alternative therapies and on health 
behaviors (nutrition, consumption of alcohol, and smoking). 
Differences can also be observed between databases in the 
laboratory, radiology and pathology data captured and in the 
types of patients/treatments captured – CaPSURE includes 
all types of treatments whereas K-CaP and J-CaP only include 
RP, radiotherapy and hormone therapy. To date, only K-CaP 
has established a tissue bank and collects urodynamic data. 
Table 1. Comparison of data collected in the K-CaP, J-CaP, and CaPSURE databases 
Measurement K-CaP J-CaP CaPSURE
Patient information
Demographics: age, gender, race × × ×
Body measurement: height, weight, body mass index × × ×
Past history: comorbidities, surgical history, family history × × ×
CAM/health behaviors: alcohol, nutrition, smoking, CAM treatment, vitamins, herbs, nutritional  
   supplements
×
Laboratory/radiology/pathology
Hemoglobin × × ×
Prostate-specific antigen × ×
Radiology: bone scan, MRI, CT × ×(NE)
Pathology
Biopsy × × ×(NE)
Pathology × ×(NE)
Survey
International Prostate Symptom Score × ×
International Index of Erectile Function × ×
Continence ×
Quality of life according to patients and physiciansment ×
Treatment
Radical prostatectomy × × ×
Radiotherapy × × ×
Hormone therapy × × ×
Active surveillance ×
Brachytherapy ×
Cryotherapy ×
Hormone refractory and chemotherapy agents 
Other
Concomitant medication: cardiovascular, antihypertension, statins, diabetes medication, other  ×
Survival × × ×
Biobank ×
Urodynamic data ×
K-CaP, Korea Study Group of prostate cancer; J-Cap, Japan Study Group of prostate cancer; CaPSURE, cancer of the prostate strategic urologic research 
endeavor; CAM, complementary and alternative medicine; MRI, magnetic resonance imaging; CT, computed tomography; NE, not exact.
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2.  Comparison of outcomes among prostate cancer 
patients treated with PADT or radical prostatectomy 
at Seoul St. Mary’s Hospital 
Presented by Ji Youl Lee
Dr. Ji Youl Lee provided an overview of recent data generated 
from the Seoul St. Mary’s Hospital prostate cancer database–
one of the contributing institutions to the K-CaP initiative–
regarding risk assessment and a comparison of outcomes 
amongst patients receiving primary androgen deprivation 
therapy (PADT) and those undergoing RP. He reminded the 
participants that the K-CaP team had first participated in 
the Fifth J-CaP and CaPSURE Joint Meeting in 2011 in Tokyo 
and had started developing the K-CaP database around that 
time. As discussed by Dr. Choi in her presentation, the K-CaP 
database currently receives information from five large hos-
pitals in Korea (Severence Hospital, Seoul National University 
Hospital, Asan Medical Center, Samsung Medical Center, and 
Seoul St. Mary’s Hospital) which together treat around 50% of 
the prostate cancer patients around the country. Last year saw 
the inaugural meeting of the K-CaP group in Daegu, Korea, 
to discuss progress and plan the next steps for the initiative. 
He advised that there are now plans to extend the database to 
include other hospitals around the country.
 The prevalence of cancers among Korean men is rapidly 
changing, with prostate cancer now being the third most 
prevalent (8.9%) after stomach and colon cancer [1]. How-
ever, Dr. Lee noted that survival for patients with prostate 
cancer has increased over the last decade and that treatment 
decisions are also changing.
 For advanced prostate cancer patients in Korea, PADT is a 
standard treatment modality resulting in the best outcomes 
for survival and quality of life (QoL). In localized prostate can-
cer however, RP is the standard treatment modality as it can 
achieve a complete cure for localized disease and the use of 
PADT is still controversial in this setting. However, an analysis 
of the database shows that patients receiving PADT tend to 
be older, less educated, and on a lower income, and that their 
survival and disease control appear to be affected by their 
socio-economic status. Dr. Lee considered that the potential 
benefits of PADT in clinically localized prostate cancer need to 
be re-evaluated in a large patient population and went on to 
present data on the use of PADT at Seoul St. Mary’s Hospital. 
 Demographic data for prostate cancer patients who were 
treated with PADT or RP showed differences in age distribu-
tion ( < 60, 60–70 or > 70 years), PSA level, clinical stage and 
Gleason score (GS). A comparison of patients who had re-
ceived PADT at St. Mary’s Hospital with J-CaP and CaPSURE 
data showed a similar data pattern to J-CaP in terms of age 
distribution, GS, clinical stage and risk group. In contrast, the 
type of primary therapy for low-risk prostate cancer patients 
at St. Mary’s Hospital was very similar to that seen in CaP-
SURE, being predominantly RP. A comparison of risk stratifi-
cation using the D’Amico classification found a similarity in 
the distribution pattern between St. Mary’s Hospital and J-
CaP data with both being quite different to that pattern seen 
in CaPSURE. In general, CaPSURE data showed a larger pro-
portion of low risk patients and a smaller proportion of high 
risk patients across all age ranges compared with the other 
two cohorts.
 Focusing on data from St. Mary’s Hospital, Dr. Lee showed 
an analysis of disease recurrence and survival comparing pa-
tients who had received PADT with those who had received 
RP. Follow-up in both cohorts of patients was five years. This 
showed that in localized prostate cancer patients, there is no 
difference in recurrence between those treated with PADT 
or RP but noted that when making a choice of treatment the 
potential adverse effects of each therapy needed to be taken 
into consideration. However, in terms of survival, differences 
can be observed between PADT and RP for the treatment of 
both localized and advanced disease. Dr. Lee noted that these 
results were similar to those reported for 10-year survival in 
another study of Japanese patients comparing luteinizing hor-
mone releasing hormone (LHRH) agonist monotherapy and 
RP [2]. In that study, patients who received either PADT or RP 
had a similar life-expectancy to that of the normal population. 
 Multivariate logistic regression analysis of the Seoul St. 
Mary’s Hospital data showed that the risk factors for recur-
rence in advanced prostate cancer patients receiving PADT 
are Gleason grade, T stage and PSA level. The risk factors for 
survival in localized and advanced prostate cancer patients 
receiving PADT or RP is the treatment modality itself. He con-
sidered that these interesting results warranted further evalu-
ation in a larger patient population, including an analysis of 
the whole K-CaP database.
 Dr. Lee concluded his presentation by giving an introduc-
tion to the Asian Pacific Prostate Society (APPS; http://ap-
prostate.org/). The APPS was established by a gathering of 
renowned urologists on prostate health and disease factors 
from 11 countries worldwide, not only from Asia but also from 
the rest of the world including Australia, the United States, 
and Canada. Participating Asian countries included Korea, 
China, Japan, Taiwan, Singapore, the Philippines, Malaysia, 
Indonesia, and Hong Kong. The aim of the APPS is to pro-
vide a forum for urologists to exchange their ideas regarding 
basic and clinical research studies on prostate health and 
disease. In addition, APPS leads the way in multinational and 
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multicentered clinical research studies in the Asia–Pacific 
region, and holds an annual meeting to develops treatment 
guidelines for the this region. It also has its own official jour-
nal: Prostate International which publishes clinical research 
articles, basic research articles, and clinical trials reporting the 
latest data on prostate cancer, benign prostatic hypertrophy 
and prostatitis. APPS is now developing a combined Asian 
database system and have a Korean prostate biobank that col-
lects samples from several hospitals. Around 200 urologists 
attended the recent APPS 2013 meeting in Melbourne, Aus-
tralia. The APPS 2014 meeting will be held in Okinawa, Japan 
in March 2014 and will be hosted by Shigeo Horie, Professor 
of Urology at Juntendo University School of Medicine, Tokyo, 
Japan. 
3.  Determining the triggers for intervention among 
men undergoing active surveillance for prostate 
cancer  
Presented by Byung Ha Chung
Professor Chung, current President of the APPS, discussed 
which factors determined the triggers for intervention 
amongst men undergoing active surveillance (AS) for pros-
tate cancer. A recent publication from his institution had ana-
lyzed the trends in prostate cancer management and patient 
characteristics over five years due to the significant increase 
in prostate cancer incidence and the introduction of robotic 
equipment in Korea [3]. They found that as the incidence 
increased, the proportion of localized and locally advanced 
cancer had also increased. In addition, the most commonly 
used treatment modality had changed from nonsurgical 
treatment to RP. 
 Professor Chung also noted that the establishment of the K-
CaP database was announced in another recent publication 
to provide urologists with details of its methodology and an-
ticipated future development [4]. K-CaP is the first database 
of comprehensive, observational, longitudinal data about 
prostate cancer patients in Korea and includes information 
covering a range of treatments, both surgical and nonsurgical. 
Professor Chung reported that in Korea, the concept of ‘active 
surveillance’ as a treatment option has only been accepted 
in the past few years. He described a study undertaken at his 
institution to compare contemporary AS protocols based on 
pathological outcomes in 1,662 patients who had undergone 
RP [5]. Experimental cohorts were identified from prostate 
cancer patients who had undergone RP between 2001 and 
2011, and who met the inclusion criteria of five published 
AS protocols, namely: Johns Hopkins Medical Institution, 
University of California at San Francisco, Memorial Sloan-
Kettering Cancer Center, University of Miami and Prostate 
Cancer Research International: Active Surveillance. A total of 
376 patients met the criteria for AS according to these proto-
cols. According to the investigators these protocols showed 
similar pathological characteristics in patients who had un-
dergone RP, however they concluded that the Prostate Cancer 
Research International: AS protocol was likely to be the most 
suitable for the Korean population when selecting candi-
dates for AS considering the balance between sensitivity and 
specificity, and the accuracy of diagnosis. A comparison of 
the Korean data with that of a similar study of 391 Western AS 
candidates found more adverse prostate cancer features (GS, 
8–10 and/or extracapsular extension and/or seminal vesicle 
involvement) among Korean patients than their western 
counterparts [6]. Professor Chung said that this highlighted 
the importance of carefully selecting candidates for interven-
tion among patients undergoing AS.
 Professor Chung went on to review the various strategies 
for deciding whether to intervene during AS, including PSA 
kinetics, a confirmatory repeat biopsy, novel biomarkers, or 
diffusion-weighted multiparametric MRI. He reminded par-
ticipants that the debate continues as to the most appropriate 
eligibility criteria for AS and what triggers for intervention 
should be considered [7]. Studies assessing the association be-
tween various clinical characteristics and unfavorable repeat 
biopsy results show that there is currently no general con-
sensus regarding PSA kinetic parameters (PSA density, PSA 
doubling time and PSA velocity) or cutoff values for predict-
ing disease progression. Professor Chung advised that in fact, 
several reports suggest that PSA kinetics should not be used to 
assist decision making during AS [8-11].
 Confirmatory repeat biopsy is a method commonly used 
to assess the need for intervention. However, in around 28% 
of cases there is pathological upgrading following the biopsy, 
reflecting a reclassification rather than disease progression. It 
has been shown that low-risk tumors that are later reclassified 
as high-risk have a worse prognosis so the recommendation 
is to perform a confirmatory biopsy early, within one year 
of initial diagnosis [12]. However, there is still a lack of con-
sensus and limited follow-up data regarding the size of the 
tumor and the GS that should trigger intervention. A recent 
review concluded that AS is a well-tolerated treatment option 
in carefully-selected groups of patients. However, the authors 
recognized that there are no over-arching criteria for patient 
selection or triggers for intervention and that decisions need 
to be guided by individual patient histology, PSA kinetics and 
imaging information [7].
 Various biomarkers have also been investigated as poten-
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tial triggers for intervention. PCA3, a prostate specific non-
coding mRNA that is significantly over expressed in prostate 
cancer tissue, is not significantly associated with short-term 
biopsy progression in men with low-risk prostate cancer 
undergoing AS [13]. Another study has shown a significant 
correlation between serum and tissue levels of another bio-
marker, pro-PSA, at diagnosis and the need for subsequent 
treatment. The study also suggested that the increase in the 
ratio of serum pro-PSA: percentage free PSA might be driven 
by increased pro-PSA production from ‘premalignant’ cells in 
the prostate benign-adjacent areas [14]. 
 Professor Chung advised that recent data suggest that intra-
prostatic imaging using MRI can help improve the selection 
of candidates for AS [15]. Two studies from Professor Chung’s 
own research group also supported these findings [16,17]. 
The first study showed that that a simple measurement of the 
diameter of suspicious tumor lesions on diffusion-weighted 
MRI could improve the prediction of insignificant prostate 
cancer in patients who are candidates for AS [16]. The second 
study found that tumor visibility on multiparametric MRI 
was a predictor of favorable disease for those prostate cancer 
patients who did not meet the criteria for AS (Table 2) [17]. A 
retrospective analysis was undertaken of 464 prostate cancer 
patients with clinically localized disease who had undergone 
multiparametric MRI before RP. Of these, 238 were eligible for 
AS (group 1) and 226 were not. These 226 patients were divid-
ed into two groups according to the result of multiparametric 
MRI: 59 patients (26.1%) with no visible tumor (group 2) and 
167 patients (73.9%) with visible tumor (group 3). 
 The proportions of organ-confined, Gleason ≤ 6 disease 
and unfavorable disease were 63.9 and 11.3% in group 1, 59.3 
and 10.2% in group 2, and 38.9 and 22.8% in group 3. Com-
paring groups 1 and 2, these proportions were not statistically 
different (P= 0.549 and P= 1.000, respectively). However, 
comparing groups 1 and 3, they were significantly different 
(P< 0.001 and P= 0.002, respectively). In multivariate logistic 
regression analysis, no visible tumor on multiparametric MRI 
was an independent predictor of organ-confined GS 6 dis-
ease (odds ratio, 0.426; P= 0.007) but there was no statistically 
independent predictor for unfavorable disease. It was con-
cluded that this imaging technique might help to determine 
the most appropriate treatment modality for low-risk prostate 
cancer patients who consider AS as an option even if they do 
not meet standard criteria.
 Within the CaPSURE database, it was noted that the num-
ber of patients undergoing AS was quite low compared to 
the number of low-risk patients who were candidates for this 
treatment option. Participants considered that there were 
probably multiple reasons for the low uptake of AS–patients 
often did not understand the concept of not treating cancer 
while physicians were trained to treat it. It was commented 
that that each of these prostate cancer databases should not 
only be used as tools for research but also for quality im-
provement and should be able to feed back to the participat-
ing institutions about how they are performing and how they 
could improve their treatment practices.
 
4.  J-CaP prospective observational study: background 
factors of patients who underwent PADT or radical 
prostatectomy for localized prostate cancer 
Presented by Satoru Ueno
Dr. Ueno discussed the findings of a J-CaP prospective obser-
vational study undertaken at his institution to investigate the 
background characteristics of patients who had undergone 
RP or PADT for localized prostate cancer.
 To introduce his presentation, he highlighted the results of 
two similar studies in this setting. The first was a retrospec-
tive study comparing the outcomes of patients treated with 
PADT with those treated with RP [18]. The results showed 
that disease-specific survival rates of relatively younger pa-
tients with performance status 0–1, who were generally good 
candidates for RP, were surprisingly similar between the two 
groups, even after 10 years of follow-up. While PADT, as ex-
pected, did not provide long-term efficacy in cases of poorly-
differentiated adenocarcinoma, it was found that none of the 
patients with well-differentiated adenocarcinoma who had 
been treated with PADT died from prostate cancer during the 
10-year observation period.
 In light of these results, the investigators had decided 
to evaluate which types of prostate cancer were potential 
candidates for PADT and had conducted another retrospec-
tive study [19]. A total of 628 patients with T1c–T3 prostate 
cancer without metastasis were analyzed. A comparison of 
Table 2. Comparison of pathologic outcomes between active 
surveillance candidates (group 1) and nonactive surveillance 
candidates without visible tumor on multiparametric magnetic 
resonance imaging (group 2)
Variable Group 1 Group 2 P-value
Tumor volume (cm3) 0.81±0.78 0.93±0.85 0.959
Organ-confined, Gleason score 
   6 disease
152 (63.9) 35 (59.3) 0.549
Insignificant prostate cancer 81 (34.0) 16 (27.1) 0.354
Unfavorable disease 27 (11.3) 6 (10.2) 0.999
Values are presented as mean ±standard deviation or number (%). 
Adapted from Lee DH, et al. Jpn J Clin Oncol 2013;43:553-8, with permis-
sion of Oxford University Press [17].
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combined androgen blockade (CAB) treatment with castra-
tion monotherapy, found that disease-specific survival in the 
CAB group was significantly higher than that of the castration 
monotherapy group: 92.8% versus 78.5% survival at 10 years, 
respectively (P= 0.037).
 According to D’Amico risk grouping, the outcomes of pa-
tients in the low- and intermediate-risk groups, a total of 331 
patients, were satisfactory. These 331 patients were divided 
into two groups based on the time to nadir PSA levels after 
the commencement of hormonal therapy, with a PSA level of 
< 0.2 ng/mL being defined as the nadir. PSA levels decreased 
to the nadir level within 6 months in 192 patients; these pa-
tients were designated as group G (good response group). 
The remaining 139 patients whose PSA did not decrease to 0.2 
within 6 months were designated as group P (poor response 
group). The 10-year disease-specific survival rate of group G 
was excellent (98.9%) and notably no cancer-related deaths 
were observed during this period among group G patients re-
ceiving CAB treatment. In addition, the progression-free sur-
vival rate of patients treated with CAB in group G was 87.2% 
at 10 years compared with 79.4% in the monotherapy group 
(P= 0.45). Therefore, a long-term survival rate of more than 10 
years can be expected with CAB treatment.
 Dr. Ueno noted that while these initial studies suggested 
PADT was effective in some patients in the early stage of pros-
tate cancer it was recognized that more comparative studies 
were needed to elucidate the usefulness of this approach. 
To address this issue, his research team had initiated a new 
clinical study, the J-CaP Innovative Study-1. Although this 
study is an observational trial, this type of prospective, com-
parative study has never been undertaken before. Patients 
aged 67–76 years with localized prostate cancer and clinical 
stage T1c or T2 disease, a PSA of < 20 ng/mL, and a GS of ≤ 7 
were enrolled in the study. The mean age was 71.0 and 73.0 
years for the RP and PADT groups, respectively. In both the 
groups, more than 90% of patients had a good general status 
(performance status = 0). Patients with the PSA level < 10 ng/
mL accounted for 70.4% of the RP group and 59.5% of the 
PADT group. The proportion of the patients with high PSA 
levels (15–20 ng/mL) was greater in the PADT group. Around 
50% of patients in each group had a total GS of < 7. Similarly, 
patients with the GS of 7 accounted for 50.4% of the RP group 
and 47.8% of the PADT group. 
 Patients with stage T1c cancer were the most common, 
constituting approximately 65% in each group (Fig. 1). In ad-
dition, patients with stage T2a cancer accounted for 30.6% in 
the RP group and 21.6% in the PADT group. Dr. Ueno noted 
that considering that most participants were elderly patients, 
it was to be expected that many had coexisting diseases. He 
considered that many patients in the PADT group might have 
been treated with this therapy due to the potential risk of 
surgery in patients with established cardiovascular or lung 
disease. The reason for the selection of treatment regimen 
and who made the decision regarding the treatment were 
therefore investigated. In both the groups, the patient’s choice 
of treatment was a major factor in deciding therapy. It may be 
that younger age is a factor in the decision to select RP while 
comorbidities are the reason why the patients choose PADT.
 
5.  QoL surveillance data for patients who underwent 
PADT or radical prostatectomy (J-CaP study data)
Presented by Satoru Ueno
In his second presentation, Dr. Ueno reviewed the QoL sur-
vey results of the J-CaP study comparing PADT and RP treat-
ments which had been estimated using the 8-item, short-
form generic health-related QoL questionnaire (SF-8) and ex-
panded prostate cancer index composite (EPIC) instruments. 
These questionnaires were prospectively administered before 
treatment and during follow-up at 3 and 12 months.
 The SF-8 instrument contains eight scales (physical func-
tion, role physical, bodily pain, general health, vitality, social 
function, role emotional, and mental health) that gener-
ate physical and mental component summary scores. The 
completion rates for SF-8 at each time point were consider-
ably high, even 12 months after the initiation of treatment. 
At 12 months, the completion rates were 76.8% in the RP 
group and 75.6% in the PADT group. In the RP group, scores 
for each SF-8 domain, except for mental health, decreased at 
3 months following surgery. However, their scores returned 
to pretreatment levels one year following the surgery. The 
mental component summary score increased over time. In 
Fig. 1. T-category distribution amongst patients with localized 
prostate cancer treated with primary androgen deprivation 
therapy or radical prostatectomy in the J-CaP Innovative 
Study-1. J-CaP, Japan Study Group of prostate cancer.
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contrast, for the PADT group the scores for some domains, 
including physical function, decreased slightly. However, the 
scores for mental health increased over the one year of treat-
ment. No significant differences were observed between the 
two groups at 12 months for the scores of individual domains.
 The EPIC instrument contains 50 items from five scales 
(urinary incontinence, urinary irritative-obstructive, bowel, 
sexual and hormonal), with scores ranging from 0–100. Par-
ticipants queried which QoL instrument was the best to use 
for studies of patients with prostate cancer. It was noted that 
the CaPSURE team generally used the EPIC-26 instrument, a 
shorter version of the EPIC-50, in clinical practice at Univer-
sity of California, San Francisco (UCSF) and were moving to 
this for CaPSURE. 
 In Dr. Ueno’s study, the completion rates for EPIC at each 
time point were considerably high, similar to SF-8. Even 
after 12 months, the completion rates were 75.9% in the RP 
group and 72.9% in the PADT group. The mean urinary scores 
for surgical patients decreased at 3 months posttreatment 
and improved at 12 months but remained lower than those 
at baseline. The section of hormonal function in the EPIC 
questionnaire includes hot flashes and breast tenderness; 
therefore, as expected the scores in this section for patients 
receiving PADT gradually decreased over time compared 
with those of RP patients. The mean score of the sexual do-
main in both the groups was already low at baseline and 
exhibited a decline at 3 months after treatment which did not 
return to baseline. The differences in urinary and sexual QoL 
scores between RP patients receiving nerve-sparing and non–
nerve-sparing procedures were not clinically significant. A 
comparison of the subscale scores between the two patient 
populations showed that baseline QoL was almost the same 
in both the groups (Fig. 2). However, the subscale scores of 
urinary and sexual function at 3 months for RP patients were 
significantly lower than those for patients who received PADT. 
While these scores improved at 12 months, they did not re-
turn to baseline. Dr. Ueno considered it was notable that in 
patients treated with PADT, sexual bother did not decrease 
despite a considerable decrease in sexual function after the 
initiation of PADT. He proposed that this is reason why many 
Japanese patients are happy to receive PADT.
 In terms of overall satisfaction scores, the numbers of pa-
tients with increased and decreased satisfaction were almost 
equal in the RP group. In contrast, in the PADT group, the av-
erage satisfaction tended to increase over the one-year treat-
ment period.
Fig. 2. Subscale score of the expanded prostate cancer index composite instrument in patients with localized prostate cancer treated 
with primary androgen deprivation therapy or radical prostatectomy.
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 Dr. Ueno concluded by noting that various considerations 
were involved when choosing a treatment for prostate cancer 
patients. Urologists tended to emphasize the outcome and 
QoL. However, many patients may favor a less invasive treat-
ment, and they will ultimately choose a treatment based on 
their personal preferences. Although few clinical practice 
guidelines recommend PADT as an option for the treatment 
of localized prostate cancer, many patients, particularly in Ja-
pan, prefer to receive PADT rather than surgery. 
 
6.  Recent trends in initial therapy for newly-diagnosed 
prostate cancer (J-CaP surveillance data) 
Presented by Mizuki Onozawa                                                                                                      
Dr. Onozawa provided an update on a J-CaP surveillance 
study undertaken to evaluate initial therapy for newly-diag-
nosed prostate cancer. Firstly, he reviewed the background, 
objectives and protocol for the study noting that over the pre-
vious decade in Japan, the value of PSA screening had been 
the subject of much discussion and had become widely rec-
ognized by both physicians and amongst the general popula-
tion. New treatment technologies, such as intensity modu-
lated radiotherapy (IMRT) and robotic surgery, had been 
introduced and their usage had increased. Overall, the clinical 
practice pattern of prostate cancer had changed considerably.
 The objective of the J-CaP surveillance study 2010 was to 
investigate the trends over time in patient characteristics at 
the point of diagnosis of prostate cancer and in the choice of 
initial treatment. Inclusion criteria for the study were patients 
with histologically-proven, newly-diagnosed prostate cancer 
whose treatment started between 1st January 2010 and 31st 
December 2010. Each patient’s background characteristics 
and initial treatment for prostate cancer were recorded in a 
multi-institution, cross-sectional, retrospective, observational 
study undertaken nationwide across Japan. Registration of 
patients started in 2011 and closed on 30th September 2012.
 A total of 9,011 patients were registered and data for 8,326 
of these patients from 140 institutions (37 university hospi-
tals, 52 public hospitals, 51 private hospitals) was analyzed. 
The following patient characteristics were recorded: age, 
any comorbidity, TNM and clinical stage, PSA, GS, and risk 
score (D’Amico, Cancer of the Prostate Risk Assessment 
[CAPRA], Japan-CAPRA [J-CAPRA]). Initial treatments were 
also recorded (RP, radiation therapy, PADT). These data were 
descriptively analyzed and compared with those from other 
studies undertaken in Japan (Japanese Urological Associa-
tion [JUA] 2000 [20], JUA 2004 [21], J-CaP 2001–2003 [22]) and 
the US (CaPSURE [23,24]; National Prostate Cancer Registry 
[NPCR], and Surveillance, Epidemiology, and End Results 
[SEER] Program 2001–2007 [25]). 
 The median age at the diagnosis in the J-CaP surveillance 
study 2010 (J-CaP 2010) was 71 years. The proportion of 
younger patients ( < 70 years.) in JUA 2000 [20], JUA 2004 [21] 
and J-CaP 2010 was 33%, 37% and 43%, respectively.
 The proportion of patients with T1 disease was 42% in J-CaP 
2010 compared with 26% in JUA 2000 [20] and 39.7% in JUA 
2004 [21]. T3 and T4 disease were observed in 18% and in 4% 
of the patients, respectively. The proportion of T3–4 disease 
was much higher in J-CaP 2010 than reported in CaPSURE 
(4%–5%) [24,26]. The proportion of patients with M1 disease 
was 11% in J-CaP 2010 compared with 23% in JUA 2000 [20], 
12% in JUA 2004 [21], and 3% in NPCR and SEER 2001–2007 
[25]. The proportion of patients with Stage I–II disease was 
74% and 81% in J-CaP 2010 and in NPCR and SEER 2001–2007 
[25], respectively. The reason for the increase in the proportion 
of patients diagnosed with localized disease was queried in 
light of the fact that PSA screening is not undertaken routinely 
in Japan. It was suggested that in clinical practice both physi-
cians and patients were now more aware of the availability of 
screening and wanted to be tested.
 The proportion of patients with PSA < 10 ng/mL in J-CaP 
2010 was 49% compared with 30% in JUA 2000 [20] and 39% 
in JUA 2004 [21]. The proportion of patients with PSA ≥ 100 
ng/mL in J-CaP 2010 was 9% compared with 12% in JUA 2004 
[21]. When GS was categorized into three groups, they were 
almost equally distributed. The proportion of GS < 7 was 39% 
and 64% in JUA 2004 [21] and CaPSURE, respectively [24]. 
Risk assessment showed that J-CaP 2010 included a greater 
number of higher risk patients compared with CaPSURE [24]. 
 When treatment choices were analyzed, the most fre-
quently selected initial treatment was PADT, followed by RP, 
radiation therapy and surveillance. Although this order was 
the same as found in JUA 2000 [20] and JUA 2004 [21], it was 
different from that seen in CaPSURE data. PADT was less 
frequently used in J-CaP 2010 than in JUA 2004 [21]. In CaP-
SURE data, the use of PADT has increased gradually [23]. 
 The distribution of treatment was analyzed by age and T-
category. When J-CaP 2010 was compared with JUA 2004 [21], 
the proportion of RP was not increased even in young and 
low T-staged patients. In young and low T-staged patients, 
radiation therapy use was increased and PADT use was de-
creased. PSA surveillance was selected nearly equally across 
all age groups. When analyzed according to CAPRA score, the 
proportion of patients undergoing RP was lower in those with 
a low score. PSA surveillance was selected by about 20% of 
patients with low CAPRA score. In CaPSURE, the proportion 
of patients opting for PSA surveillance was much lower, even 
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in those with CAPRA 0–2.  
 Looking at individual treatments, in JUA 2004, 89% of pa-
tients had undergone RP with an open procedure [21]. Lapa-
roscopic RP had increased from 7% in JUA 2004 [21] to 12% in 
J-CaP 2010. In Japan, robotic prostatectomy was approved in 
2009 but only 16 institutions had these facilities in 2010. Now-
adays they are installed in 130 institutions. The percentage of 
brachytherapy use in J-CaP 2010 was 46% compared with 17% 
in JUA 2004 [21] and 50% in CaPSURE [24,27]. Brachytherapy 
use tended to be lower in older patients, which is supported 
by findings from the CaPSURE database [27]. In the SEER–
Medicare database, the proportion of IMRT was six times 
higher than external beam radiation therapy (EBRT) [28]. 
 In term of PADT, the CAB/non-CAB ratio in J-CaP 2010 was 
3.5 (2.3 for Stage I–II disease, 4.8 for Stage III, and 7.1 for Stage 
IV); this ratio was 2.0 in J-CaP 2001–2003 [22] (Fig. 3). Notably, 
this increase in the use of CAB was observed at both Stage III 
and Stage IV disease. LHRH plus an antiandrogen was used 
in a substantial proportion of patients, even those with very 
low-risk disease. Surgical castration was performed in 5% of 
patients with J-CaP 2010 compared with 10% in JUA 2000 [20], 
10% in J-CaP 2001–2003 [22], and 6% in JUA 2004 [21]. 
7.  Comparative analysis of comorbidity and other  
confounding factors in patients who underwent 
PADT or radical prostatectomy for localized prostate 
cancer 
Presented by Matthew R. Cooperberg (CaPSURE) & Shiro 
Hinotsu (J-CaP)
Dr. Cooperberg presented the latest data from the CaPSURE 
database on patient comorbidities. He suggested that one of 
the possible reasons for the differences observed between 
the CaPSURE and J-CaP cohorts was the underlying diseases 
burdening prostate cancer patients. The comorbid condi-
tions that CaPSURE tracks are as follows: arthritis, blood 
disease, cancer (nonprostate), diabetes, endocrine (other), 
ENT disease, eye disease, heart disease, hypertension, infec-
tion, kidney disease, liver disease, lung disease, mental health 
conditions, stomach/intestinal disease, stroke/other neuro-
logical condition and urinary conditions. This information is 
primarily collected by patient report whereby they are asked 
to complete a survey once or twice a year to collect data on 
QoL, comorbidities etc., and are required to give simple yes/
no answers. He acknowledged that this system did have limi-
tations as no detailed information is collected, for example on 
glycated haemoglobin levels or severity of CHF. As it is self-
report, it also means that the patient could have an asymp-
tomatic condition that they are unaware of.
 Dr. Cooperberg reported that the overall prevalence of co-
morbidities in CaPSURE appears to reflect that of the general 
US population with the most common comorbidities be-
ing hypertension (~45%), arthritis (~38%) and heart disease 
(~23%) (Fig. 4). Also notable are other cancers, diabetes and 
gastrointestinal disease. In terms of comorbidity count (the to-
tal number of comorbid conditions the patient has) the modal 
number is one, which again reflects the general population. 
 When the comorbidity count was analyzed according to 
the type of primary treatment, some striking differences were 
observed between those patients undergoing surgery and 
those receiving other treatments (radiation therapy, PADT or 
watchful waiting/AS). Patients undergoing surgery tended 
to be healthier and had fewer comorbidities. There were no 
Fig. 3. Comparison of primary androgen deprivation therapy use in J-CaP 2001–3 and J-CaP 2010 studies. J-Cap, Japan Study Group 
of prostate cancer; J-CAPRA, Japan cancer of the prostate risk assessment; AA, antiandrogen CAB, combined androgen blockade; 
LHRH, luteinizing hormone releasing hormone agonist; mono., monotherapy; SC, surgical castration; L, long-term; S, short-term. 
Adapted from Hinotsu S, et al. Jpn J Clin Oncol 2007;37:775-81 [22]. 
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significant differences between the other treatment groups in 
terms of comorbidity count. 
 Dr. Cooperberg then went on to show data for some of the 
major comorbidities analyzed over time and according to 
the primary therapy the patient received. Around 8% of men 
undergoing RP self-reported with diabetes and surprisingly 
this did not change significantly over time (since around 
1990) despite the recognized increase in obesity, metabolic 
syndrome etc. in the US. This figure was around 12% for those 
who underwent radiation therapy, 14% for those treated with 
PADT and 14% for those who underwent watchful waiting/
AS. No significant trends over time were observed for any of 
the treatment groups. 
 A similar pattern was observed for hypertension: around 
48% of patients in all treatment groups with minimal trends 
over time. Differences were observed however for heart 
disease: Only 15% of men undergoing RP reported having 
heart disease whereas these figures were much higher for 
other treatments: radiation, 31%; PADT, 31% and watchful 
waiting/AS, 34%. Again, there were limited trends over time 
in each group. Another notable difference for patients un-
dergoing surgery were a higher reporting of genito-urinary 
disease compared with those undergoing other treatments. Dr. 
Cooperberg considered that all of these observed trends prob-
ably just reflected the patient’s age as patients in CaPSURE 
undergoing surgery tended to be younger than those receiving 
other therapies.
 A multinomial regression analysis (adjusting for practice 
site) was undertaken to look at possible predictors of treat-
ment. This showed that if adjusting for individual comorbidi-
ties rather than comorbidity count, then hypertension, stroke, 
diabetes, heart disease, and blood disease were predictors of 
nonsurgical therapy. Income remains a predictor of surgical 
therapy, while education and race are less significant.
 In terms of overall survival, the main comorbidities (heart 
disease, stroke, diabetes, and lung disease) and treatment 
with PADT are all predictors of a shorter survival while under-
going surgery predicts longer survival. In a competing risks 
survival analysis model, none of the comorbidities appeared 
to be a predictor of mortality while a high CAPRA score was 
predictor of shorter survival. Compared to radiation therapy, 
treatment with PADT predicts shorter survival while surgery 
improves survival, after adjusting for competing risks.
 Professor Hinotsu then presented data from J-CaP on a 
comparative analysis of comorbidity and other confounding 
factors for patients who have undergone RP and PADT for 
the localized prostate cancer. The most common comorbid-
ity in J-CaP was hypertension (~30% of patients) followed 
by heart disease (~15%); other comorbidities tended to be 
≤ 10%. When comparing with CaPSURE, it was apparent that 
CaPSURE patients appeared to have a higher burden of co-
morbidity than those in J-CaP in particular for hypertension, 
heart disease, and diabetes.
 He noted that one of the limitations of the web reporting 
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system was that it was not possible to distinguish between the 
answer ‘no’ and missing data. In addition, in many cases it is 
not possible to obtain detailed medical records data from the 
hospital to verify any missing information as in Japan they are 
only required to keep the records for five years. 
 As a result, Professor Hinotsu advised that they had focused 
on other possible confounding factors, including T stage. It 
was noted that J-CaP used the 1997 T-stage classification sys-
tem while CaPSURE used the 2002 version, so slight adjust-
ments had been made for comparative purposes (T2a in the 
1997 system=T2a+T2b in 2002/2009 system, while T2b in the 
1997 system =T2c in 2002/2009 system). A comparison of T-
stage distribution for J-CaP and CaPSURE showed that in the 
J-CaP cohort had a much higher proportion of stage T2c, T3a, 
and T3b patients than CaPSURE. He considered that one of 
the possible reasons for this was that the diagnosis of T stage 
might be different between J-CaP and CaPSURE. He noted 
that clinical practice guidelines issued by the JUA [29] recom-
mended MRI for identification of the stage of locally advanced 
disease so this had become routine practice in Japan. Accord-
ing to the National Comprehensive Cancer Network (NCCN) 
guidelines published in the US, MRI is not mandatory [30]. 
 Professor Hinotsu went on to present Kaplan–Meier curves 
for cause-specific survival according to T stage in J-CaP and 
CaPSURE for intermediate risk patients (J-CAPRA score, 3–7) 
(Fig. 5). Patients categorized at T stage 3 in J-CaP appeared 
to have a worse prognosis than similarly staged patients in 
CaPSURE. These results suggest that the difference between 
T-stage categorization of the two databases equates to a 1 or 
2 point difference J-CAPRA score. While this is not a major 
confounding factor, it contributes to the overall clinical pic-
ture. Professor Hinotsu summarized by recommending that 
further analysis is needed to uncover other confounding fac-
tors between J-CaP database and CaPSURE database. 
 The importance of collecting comorbidity data within 
the databases was highlighted, since they were not part of a 
randomized trial. This would allow examination of any con-
founding factors that might influence patient survival.
8.  Consideration of the reasons underlying the trans-
Pacific variation in outcomes for men treated with 
PADT for localized prostate cancer
Presented by Matthew R. Cooperberg (CaPSURE) & Shiro 
Hinotsu (J-CaP)
Dr. Cooperberg and Professor Hinotsu presented an update 
on the manuscript that was about to be submitted for publi-
cation which reported J-CaP and CaPSURE data on outcomes 
of patients treated with PADT for localized prostate cancer. 
The data had been presented by Professor Hinotsu at this 
year’s annual meeting of the American Urological Association 
(AUA) and had been reviewed at the Sixth Joint Meeting of J-
CaP and CaPSURE in San Francisco, US. 
 As background to this, Dr. Cooperberg reminded everyone 
that there was a significant discrepancy between US and 
Asian guidelines on recommendations for the use of PADT 
in localized disease. The NCCN Asia Consensus statement 
says that androgen deprivation monotherapy is an option for 
all men except those with very low-risk disease and he noted 
that there is a much greater published experience in Asia with 
the use of PADT this setting [31]. The goal of this publication 
therefore was to analyze the two databases to try and deter-
mine any differences in outcomes of patients undergoing 
PADT for localized disease. Risk adjustment had been under-
taken using the J-CAPRA scoring system.
 In terms of age at diagnosis, those in J-CaP tended to be 
older than those in CaPSURE. There was more comorbidity in 
the CaPSURE cohort compared with J-Cap, recognizing that 
there are differences in data collection between the two data-
bases. Regarding the type of PADT, orchiectomy was relatively 
uncommon in both cohorts. Notably, 67% of patients in J-
Fig. 5. Kaplan–Meier curves for cause-specific survival according to T stage in J-CaP (A) and CaPSURE (B) for intermediate risk patients 
(J-CAPRA score, 3–7). J-Cap, Japan Study Group of prostate cancer; CaPSURE, cancer of the prostate strategic urologic research en-
deavor; J-CAPRA, Japan cancer of the prostate risk assessment; PADT, primary androgen deprivation therapy.
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CaP received CAB compared with 45% of those in CaPSURE. 
J-CAPRA distribution showed that the CaPSURE cohort in-
cludes a greater proportion of lower-risk patients.
 Prostate cancer-specific survival curves were very similar 
for PADT patients in the two databases for at least the first 
10 years, despite the fact that the J-CaP cohort includes men 
with higher risk disease. However, for all-cause mortality, the 
survival of J-CaP patients was significantly better than that for 
CaPSURE patients. Prostate cancer-specific mortality (PCSM) 
was analyzed according to J-CAPRA risk category (low, 0–2; 
intermediate, 3–6; high, ≥ 7). For each category, lower PCSM 
was observed for the J-CaP cohort than the CaPSURE cohort. 
 Dr. Cooperberg then presented a univariate analysis of 
PCSM according to type of androgen deprivation therapy 
(orchiectomy, LHRH monotherapy and CAB) and according 
to J-CAPRA risk score. The data showed that overall within 
any given risk category there were relatively small differences, 
if any, between types of PADT. The exception is high-risk 
disease where men undergoing CAB appear to have a better 
survival than those receiving LHRH monotherapy (Fig. 6). 
Using a multivariable competing risks model, if the analysis is 
restricted to high-risk (J-CAPRA > 6) men, then CAB is associ-
ated with better survival than LHRH monotherapy. This phe-
nomenon is seen in the J-CaP cohort but not in the CaPSURE 
cohort. Adjusting for known confounding variables the analy-
sis also showed that over time, men were 60% less likely to die 
in the J-CaP cohort than in the CaPSURE cohort (hazard ratio, 
0.42; 95% confidence interval, 032–0.56; P< 0.001). The differ-
ence in outcomes with CAB and LHRH monotherapy seen in 
the J-CaP cohort appear to be driven by the very high-risk pa-
tients however it was noted that there are very few of these in 
CaPSURE which might explain why differences were not seen 
in that group.
 Dr. Cooperberg considered that these findings in fact vali-
date both sets of guidelines (Japanese and US), since the rec-
ommendations they state are correct for that particular popu-
lation. It was acknowledged that the results show the response 
sensitivity to CAB is different between US and Japanese 
patients with localized prostate cancer. In terms of treatment, 
however, the main difference was in the dose of antiandrogen 
used (80 mg bicalutamide was used in Japan but 50 mg in the 
US) however participants agreed that it seemed unlikely that 
this could be the primary cause of the observed results.
 Dr. Cooperberg concluded by noting that very large differ-
ences could be observed in PCSM for PADT patients in the US 
compared with Japan. There are many possible contributors 
to these variations including genetics, diet/lifestyle/environ-
ment, selection bias, era of treatment, or treatment variation, 
and these warrant further investigation.
9. Biomarker progress in the US 
Presented by Matthew R. Cooperberg
Dr. Cooperberg gave an overview of progress with identifica-
tion and use of biomarkers in prostate cancer. The overall goal 
of risk assessment in prostate cancer is to improve risk strati-
fication and to inform physician–patient decisions about the 
optimal initial treatment choice and timing of therapy. While 
numerous risk stratification instruments are available for the 
Fig. 6. A comparison of prostate cancer-specific mortality in patients undergoing combined androgen blockade in CaPSURE (A) and 
J-CaP (B). CaPSURE, cancer of the prostate strategic urologic research endeavor; J-Cap, Japan Study Group of prostate cancer; ADT, 
androgen deprivation therapy; LHRH, luteinizing hormone releasing hormone; CAB, combined androgen blockade. 
Number at risk
tx1 = ADT -orch 154 111 58 23
tx1 = ADT -LHRH 916 501 180 42
tx1 = ADT -CAB 864 420 144 41
1.00
0.75
0.50
0.25
0
Ca
us
e-
sp
ec
ifi
c m
or
ta
lit
y
0 4 8 12
Years
tx1 = ADT -orch
tx1 = ADT -LHRH
tx1 = ADT -CAB
Number at risk
tx1 = ADT -orch 859 293 54 0
tx1 = ADT -LHRH 4,508 1,880 512 0
tx1 = ADT -CAB 10,939 3,939 1,066 0
1.00
0.75
0.50
0.25
0
Ca
us
e-
sp
ec
ifi
c m
or
ta
lit
y
0 4 8 12
Years
tx1 = ADT -orch
tx1 = ADT -LHRH
tx1 = ADT -CAB
A B
CaPSURE J-CaP
Vol. 2 / No. 2 / June 2014
63
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.14047
physician to use, currently there is too much over-treatment 
of low-risk disease coupled with under-treatment of high-risk 
disease. This anomaly is something that biomarkers might 
help address.
 Recently, several studies have called into question the use-
fulness of existing methods in risk stratifying cases of localized 
prostate cancer. One study has shown that clinical T stage 
offers no independent information in predicting biochemi-
cal recurrence [32]. In addition, Gleason scoring has evolved 
over the years but there is still a lot of heterogeneity in grad-
ing, particularly for smaller volume tumors [33]. For example, 
if four cores are involved with GS 3+4, one core with GS 4+4, 
what is the overall GS? It has been found that 81% of Society of 
Urologic Oncology members will use the highest grade to de-
termine the overall score which is probably one contributor to 
over-treatment [34]. A quantitative GS has recently been pro-
posed as a modification of the current Gleason grading sys-
tem and is based on the weighted average of Gleason patterns 
present in the pathology specimen [35]. It has been suggested 
that this might improve prostate cancer risk stratification and 
help prevent the over-treatment of patients with clinically 
indolent tumors, to help select suitable candidates for AS, and 
to decide when to intervene in patients undergoing AS. 
 Dr. Cooperberg commented that the threshold for improv-
ing accuracy in predicting cancer-specific mortality after 
treatment is high as it is possible to do a lot with the patient 
information and instruments we currently have available. 
Importantly, any putative biomarker must improve on an ex-
isting clinical standard as demonstrated in a study by Shariat 
et al. [36] which confirmed that the biomarkers transforming 
growth factor-beta1 and interleukin-6 soluble receptor con-
siderably enhanced the accuracy of the standard preoperative 
nomogram for the prediction of biochemical recurrence after 
RP. 
 Although research methods for biomarker evaluation still 
lag behind those for evaluating therapeutic treatments, there 
have been considerable advances over the last decade in 
biomarker research in particular how methodology should 
be standardized to ensure accuracy of results – the Prospec-
tive-specimen collection, Retrospective Blinded Evaluation 
(PROBE) and the REporting recommendations for tumor 
MARKer prognostic studies (REMARK) guidelines are good 
examples of this [37,38]. 
 There are a huge number of candidate biomarker assays 
currently under investigation in tissue, blood and urine and 
also using novel imaging techniques. One of the key chal-
lenges deciding treatment is to determine what is an ideal 
marker to signal the endpoint of AS. Dr. Cooperberg advised 
that the tissue repository at UCSF had now been established 
for 13 years and with the currently available techniques it was 
now possible to undertake very good validation studies. 
 UCSF currently works with three companies investigating 
tissue biomarkers. They are working with Myriad Genetics on 
their cell cycle progression (CCP) assay which has been inves-
tigated in a retrospective study of two cohorts of patients with 
prostate cancer in which they measured the expression of 31 
genes involved in CCP using quantitative reverse transcrip-
tion-polymerase chain reaction (RT-PCR) on RNA extracted 
from tumor samples [39]. The results suggested that the CCP 
score was a robust prognostic marker and might have role in 
determining the appropriate treatment for patients with pros-
tate cancer. Dr. Cooperberg’s group has recently published 
a study validating the CCP score for predicting RP outcomes 
[40]. The results also showed that combining the CCP and 
CAPRA-S scores improved the concordance index for both 
the overall cohort and patients with low-risk disease. In addi-
tion, the combined CAPRA-S+CCP score consistently predict-
ed outcomes across the range of clinical risk (Fig. 7). Overall it 
was concluded that the CCP score had significant prognostic 
accuracy after controlling for all available clinical and patho-
logic data and may improve accuracy of risk stratification for 
men with clinically localized prostate cancer, including those 
with low-risk disease, who are undergoing RP. While this use 
of CCP is currently in the post-operative setting, UCSF are 
also working with Myriad Genetics to explore its use in the 
pre-treatment setting to see if it is possible to predict adverse 
pathologies.
 UCSF is also working with genomic health on the Oncotype 
Fig. 7. Prediction model for likelihood of 10-year progression 
probability for University of California, San Francisco (UCSF) 
and Scott and White Clinic (SWC) cohorts based on the com-
bined cancer of the prostate risk assessment postsurgical (CAP-
RA-S) score and cell-cycle progression (CCP) score. Dashed lines 
represent 95% confidence interval. Adapted from Cooperberg 
MR, et al. J Clin Oncol 2013;31:1428-34, with permission of 
American Society of Clinical Oncology [40].
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DX genomic prostate score (GPS), a quantitative 17-gene RT-
PCR assay using manually microdissected tumor tissue from 
needle biopsies. With the improvements in technology in re-
cent years, both the Oncotype DX GPS assay and the CCP as-
say are capable of getting good genetic signals from very small 
amounts of tumor tissue. The Oncotype DX GPS uses genes 
from four different pathways: androgen signaling, cellular 
organization, stromal response and proliferation, normalized 
to a set of five reference genes. Two major challenges have 
been addressed with this method: (1) biopsy under-sampling 
and tumor heterogeneity–genes have been identified that 
predict clinical outcome in both dominant and highest grade 
regions, and (2) very small biopsy tumor volumes–standard-
ized quantitative methods have been developed for reliable 
gene expression measurement in prostate needle biopsies. 
In fact the RNA extraction technique has been optimized to 
work with as little as 1 mm of tumor.
 Dr. Cooperberg reported that initially two large develop-
ment studies were conducted: firstly to identify genes predic-
tive of clinical recurrence and adverse pathology across mul-
tiple tumor foci within patients, and secondly to confirm the 
predictive value of these genes in prostate biopsies [41]. The 
17-gene GPS, developed from these data, was then validated 
as a predictor of true grade and stage over clinical criteria 
alone in an independent validation study of biopsies from 
patients suitable for AS. A total of 732 candidate genes were 
analyzed in the first development study (n = 441 patients) 
and 288 genes were identified that were predictive of clini-
cal recurrence regardless of Gleason patterns in separately-
sampled specimens. A total of 81 genes were taken forward 
into the second needle biopsy study of low/intermediate-
risk patients (n = 167 patients) confirmed strong association 
of the genes with adverse pathology. Multivariate analysis of 
both development studies yielded 17 genes across multiple 
biological pathways and a GPS algorithm. In the subsequent 
validation study (n = 395 patients), GPS assessed in biopsies 
from patients suitable for AS was found to be strongly predic-
tive (P< 0.005) of high grade and/or pT3 disease after adjust-
ing for CAPRA or other standard pretreatment factors. The 
addition of GPS to CAPRA also improved risk discrimination. 
While some of the GPS biomarkers in this study were related 
to metabolism, Dr. Cooperberg considered that future studies 
on tumor metabolism were likely to use novel imaging tech-
niques rather than measure circulating metabolites.
 Dr. Cooperberg noted that while these developments in 
biomarkers were extremely valuable, there was no guarantee 
that they would change clinical practice. He considered that 
the picture was in fact much more complex and that treat-
ment decisions required an array of information including 
genetics, risk scores, lifestyle and comorbidities. However, 
to actually prove that one treatment is better than another is 
more complex still. 
 With this in mind, Dr. Cooperberg informed participants 
that UCSF had just been awarded a $6 million 3-year grant 
from the US Department of Defense, the DOD Transforma-
tive Impact Award, to prove that the treatment paradigm for 
low-risk prostate cancer in the US can be changed. Currently, 
it is thought that men make treatment decisions about pros-
tate cancer therapy on poor quality information plus they 
have a limited understanding of that information. This can 
results in dissatisfaction with treatment and poor outcomes. 
The aim is to provide better information and assist patients in 
interpreting it to ultimately improve decision making, achieve 
better outcomes, higher satisfaction with treatment and less 
over-treatment. A ‘decision support system’ is being devel-
oped where trained counselors will assist patients through 
the process.
 Dr. Cooperberg also commented that biomarkers could 
prove to be a valuable tool in helping to uncover the reasons 
behind national differences in prostate cancer epidemiology 
and outcomes. He highlighted the fact that the global picture 
of prostate cancer incidence did not correlate with prostate 
cancer mortality plus there were also differences between 
countries in mortality trends over time which probably reflect 
changes in screening practices, stage migration and risk mi-
gration. Interestingly, if you take a single city in the US, such 
as Los Angeles, there are definite ethnic and racial differences 
in incidence of prostate cancer in that one city; the reasons 
for this are currently unknown.
 Dr. Cooperberg concluded that emerging biomarkers held 
great promise to improve prostate cancer risk assessment and 
reduce overtreatment. However, changing practice will take 
more than improved accuracy, and for research and clinical 
practice will require a multidisciplinary approach. Biomark-
ers may help provide guidance with respect to the timing and 
intensity of both treatment and surveillance but studies are 
required to prove this. International studies will yield fasci-
nating and critical insights into the interactions between biol-
ogy and environment. However, it was recognized that could 
be difficult to undertake any international collaborations that 
involve using tissue bank samples due to the restrictions and 
regulatory issues of transporting them between countries.
10. Plans for the development of C-CaP 
Presented by Dingwei Ye, Gang Zhu & Chi-Fai Ng
On behalf of the C-CaP Organizing Committee (Professors Na 
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Yanqun, Ye Dingwei and Chi-Fai Ng) Professor Zhu gave an 
overview of the development of the Chinese prostate cancer 
database, C-CaP. He advised that data from the Chinese Na-
tional Cancer Registration Center (1998–2009) revealed that 
prostate cancer had the fifth highest incidence of all male and 
was ninth in terms of mortality [42]. In common with other 
countries, China has an increasing ageing population with 
an average life expectancy of 71.3 years (these figures are 79.1 
years in Beijing and 80.18 years in Shanghai). In 2009, the in-
cidence of prostate cancer in China overall was an average of 
9.92/100,000; in cities it was 13.13/100,000 and in rural areas 
was 3.00/100,000. 
 Professor Zhu noted that prostate cancer was becoming 
an increasingly important issue for Chinese urologists–at the 
Chinese Urological Association Annual Meeting the number 
of clinical and basic research reports on prostate cancer had 
increased year on year. In addition, there was an increase in 
the use of minimally-invasive surgery including robotic sur-
gery for RP so this was an important area for them to focus on 
in order to improve services for patients.
 Professor Zhu reminded that attendees that the CaPSURE 
database had been founded in 1995 in the US and currently 
contains data on around 14,000 prostate cancer patients. The 
J-CaP database was established in 2001 and the J-CaP and 
CaPSURE Joint Initiative was established in 2007. Following 
discussions between Professor Na Yanqun and Professor 
Akaza, they had decided to establish C-CaP.
 The aims of C-CaP are to gather information about Chinese 
prostate cancer patients from the top 20 urological depart-
ments in China, including Hong Kong. This will then allow 
analysis, review and comparison of data on Chinese prostate 
cancer patients and evaluation of the outcomes of treatment 
in order to develop a better understanding of the disease pro-
cess in Chinese patients. C-CaP also plans to provide clinical 
evidence for the development of guidelines regarding opti-
mal prostate cancer treatment regimens. Ultimately, it is also 
hoped they can contribute to the Joint Meetings between C-
CaP, J-CaP, K-CaP, and CaPSURE.
 Professor Zhu advised that C-CaP planned to gather the 
following patient information: hospital information, patient 
characteristics, PSA, testosterone, biopsy data, cancer charac-
teristics, comorbidity, hormonal therapy, surgical procedures, 
radiation therapy, chemotherapy, active surveillance, other 
treatment options, and patient status. Descriptive results of 
sub-groups categorized by age, cancer characteristics and 
risks will also be analyzed.
 The C-CaP database is currently under construction and is 
mainly based on translation of the J-CaP database. Once the 
C-CaP data base is set up, they plan to undertake an experi-
mental run in 5–10 centers (December 2013) and then for-
mally launch it early in 2014 with the first publication of data 
by the end of 2014. 
 Professor Ng gave an overview of the situation in Hong 
Kong, since although Hong Kong is part of China they have 
different social and healthcare systems. Data from the Hong 
Kong Cancer registry in 2010 showed that in this year almost 
1,500 new prostate cancer cases were registered and it has an 
incidence of 10.7% of all male cancers (4.1% in terms of mor-
tality) [43]. The incidence of prostate cancer has been rapidly 
increasing in Hong Kong over the past 20 years. Mortality 
from prostate cancer however has remained relatively stable 
probably due to increasing public awareness of the disease 
and early detection and treatment.
 Hong Kong has a very dense population of around 7.8 
million and has a Government-subsided health care system 
similar to UK National Health Service system. It has a terri-
tory-wide electronic database system which includes most 
electronic consultation notes, operation records, imaging and 
laboratory results. In terms of prostate cancer care, there is no 
population screening policy but a recent increase in aware-
ness has prompted health checks and the identification of an 
increasing number of cases. Professor Ng advised that more 
than 90% of RP is undertaken using robotic surgery and there 
are four such systems in public hospital in Hong Kong. In 
terms of radiation therapy, image guided radiotherapy and 
IMRT are used but brachytherapy is less common. In the case 
of hormone therapy, LHRH agonists are widely available but 
the use of CAB as first-line therapy is not common.
 
11. Plans for the development of I-CaP 
Presented by Rainy Umbas
Professor Umbas gave an update on the plan for an Indone-
sian national database, the Indonesia Study Group of Prostate 
Cancer (I-CaP). This had started around three years ago with 
the intention of collecting data from three large hospitals in 
Indonesia. 
 Prostate cancer management in Indonesia currently fol-
lows guidelines published by the Indonesian Urological 
Association in 2011 [44]. Imaging is generally undertaken 
using transurethral resection of the prostate, MRI, computed 
tomography, bone scan or plain X-ray. In terms of treatment 
modalities, AS is not widely used but RP, EBRT, ADT, chemo-
therapy for castration-resistant prostate cancer and palliative 
treatment are all available.
 The next steps for I-CaP are to expand and promote the 
program to six urology training centers and their affiliates 
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(10 hospitals). They will be provided with an Excel database 
program and asked to complete their last five years’ data as 
comprehensively and accurately as possible.
 A meeting of all centers was held in February 2013 to 
discuss any issues with the database for individual centers, 
particularly in terms of the equipment they have available, 
e.g., for the determination of GS, their method of determin-
ing bone metastases and lymph node metastases, and pos-
sibilities for patient duplication especially if they have moved 
around the country. Key problems identified were errors in 
database input, missing data and patient duplication.
 The following database items are currently being collected: 
age, birth date, Karnofsky index, PSA at diagnosis, prostate 
volume, method of diagnosis, date of diagnosis, GS, TNM 
classification, number of bone lesions, disease stage, treat-
ment, date of treatment, last follow-up, date of death, and 
survival. It has been suggested that additional information 
should be collected on pretreatment body mass index, testos-
terone levels, QoL and comorbidity.
 It was recognized that while individual countries should 
develop their own national databases to suit their particular 
situations, it was important to agree on a core data set that 
would allow comparison between databases in the future.
CONCLUSION
Professor Akaza thanked all the participants for their interest-
ing and valuable contributions to the meeting. He hoped that 
the expansion of the collaborative effort would continue and 
include more countries next year. Professor Carroll extended 
his thanks to all the participants for attending, to the Korean 
team for hosting the event, and to the organizers. He added 
that each year he attended the meeting it is larger and more 
productive and he looked forward to another meeting next 
year to discuss the latest developments.
 Dr. Cooperberg reported that he and Professor Carroll had 
met with the AUA in 2009 to discuss the adoption of a nation-
al database structure for prostate cancer patients. The AUA 
board would be meeting soon to decide whether they will 
grant approval for a 3-year pilot study with 10 sites initially 
expanding to around 100 sites by the end of the 3-year period. 
It is a complex project as there are over 9,000 urologists in 
the US with a huge range of practice settings. This project not 
only offers tremendous research opportunities but can also 
be a means of improvement in quality of care. He hoped they 
would be able to report on the progress of this initiative at the 
next Joint Meeting.
 Professor Chung closed the meeting on behalf of the Ko-
rean hosts. He noted that although this was the Seventh Joint 
Meeting, Korea had only participated for the past two years 
and he was very pleased to be able to hold the current meet-
ing in Seoul. He thanked Dr. Lee for his tremendous work in 
organizing this event. Dr. Lee also extended this thanks to the 
meeting participants, in particular the co-Chairmen Profes-
sor Akaza, Professor Carroll and Professor Kim.
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